Company Overview of ImmusanT, Inc.
ImmusanT, Inc., a biotechnology company, develops treatment and diagnostic and monitoring tools to manage patients with celiac disease. The company offers Nexvax2, a peptide-based therapeutic vaccine that is designed to re-establish patients’ tolerance to the toxic effects of gluten, a protein in wheat, barley, and rye and allow them to return to a normal diet. ImmusanT, Inc. was founded in 2010 and is based in Cambridge, Massachusetts with clinical trials in New Zealand, Australia, and the United States.
One Kendall Square
Cambridge, MA 02139
Founded in 2010
Key Executives for ImmusanT, Inc.
ImmusanT, Inc. Key Developments
Similar Private Companies By Industry
|Beardsworth Consulting Group, Inc.||United States|
|Yasoo Health Inc.||United States|
|FemmePharma Global Healthcare, Inc.||United States|
|X4 Pharmaceuticals Inc.||United States|
|Aponia Laboratories Inc.||United States|
Recent Private Companies Transactions
December 19, 2014
To contact ImmusanT, Inc., please visit www.immusant.com. Company data is provided by Capital IQ. Please use this form to report any data issues.